BAT-secreted FGF21 prevents hyperglycemia and hyperlipidemia in mice [134], and FGF21 analogues tested in overweight/obese patients with type 2 diabetes mellitus have been shown to reduce dyslipidemia and hepatic steatosis, although they do not lead to improvements in glucose control and body weight [135]. The gene discussed is FGF21; the disease is metabolic syndrome.